- COMMENT
Outlook for medicines development and use in 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 24, 73-74 (2025)
doi: https://doi.org/10.1038/d41573-025-00012-2
References
Atri, A. et al. Evoke and Evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer’s disease. Alzheimers Dement. 18, e062415 (2022).
Competing Interests
The authors of this article are employees of IQVIA, a provider of data and services to the life sciences industry and to healthcare providers that works with the world's leading biopharmaceutical companies. The research for this specific article was funded by IQVIA.